Wire · regulatory
FDA's Advisory Committee Votes on Peptides: What It Does and Doesn't Do
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 July 2026 · Fusion42 review
A US FDA advisory committee recommended allowing six popular, unapproved peptides to be used by compounding pharmacies, despite regulator concerns over lack of clinical data. While advisory, the vote signals a potential legitimisation of the 'grey market' for these substances, pending a final FDA decision.
This Wire brief sits within Fusion42's coverage of Longevity & Wellness, and 12 sources have reported it between 22 Jul 2026 and 31 Jul 2026.
◆ ◆ The Wire takeaway
The 'grey market' for peptides is about to become an open, legitimate one served by compounding pharmacies. Your telehealth or wellness clinic will gain access to a regulated supply chain, but you will need a marketing strategy that works without making any clinical claims.
◆ Coverage
12 sources · first reported 22 Jul 2026 · latest 31 Jul 2026
◆ Related on Wire
◆ Topics